The Healthcare and Science business of Thomson Reuters, US, has released a white paper titled 'The Five Myths of Generic Competition.' The whitepaper highlights what originator pharmaceutical and biotech companies can do to improve their forecasting of the likely timing, source and intensity of competition from generic drugs.
The findings in the white paper are based on an independent survey of commercial professionals in pharmaceutical and biotech companies. The research, conducted by Thomson Reuters during May and June 2008, highlights a number of prevailing attitudes among commercial professionals. In analysing the study findings, Thomson Reuters offers guidance on when and how best to improve competitive intelligence processes by focusing on more effective sources of long-range signals; and by providing brand teams with the resources and tools necessary to better understand generic competition.
The white paper comes as part of Pharma Matters, a quarterly report series from Thomson Reuters. Pharma Matters covers various aspects of the pharmaceutical pipeline, leveraging strategic intelligence and competitive analysis from Newport Vision Premium, Thomson Pharma and the Thomson Messaging Mapping System.
